#United States #San Diego #DCN Dx #Lateral Flow #IVD Services

DCN Dx Showcases Expertise at 2025 Precision Med Tri-Conference

Overview

From March 11 to 13, 2025, DCN Dx will be prominently featured at the Precision Med Tri-Conference & Expo, set to take place at the Town and Country Resort in San Diego, California. With a specialization in the development and manufacturing of lateral flow diagnostics, along with IVD regulatory consulting and clinical research, DCN Dx aims to contribute significantly to the dialogue and advancements in the diagnostics field.

Key Presentations and Exhibitions

During this event, Patrick Vaughan, Ph.D., the Chief Operating Officer of DCN Dx, will present a highly anticipated talk on Day 1. Scheduled for 11:50 AM, Dr. Vaughan’s presentation will delve into the intricate challenges and real-world applications associated with an STI biomarker lateral flow assay. His discussion promises to shed light on prevalent pitfalls and potential strategies for corrective measures in diagnostic development.

In addition to the presentation, Dr. Vaughan will also present a poster outlining the regulatory navigation strategies based on a real-world case study focused on the STI biomarker lateral flow assay developed by a start-up. This poster will emphasize the essential components of regulatory engagement, study design considerations, and the impact of working with experienced partners in refining assays for commercialization.

DCN Dx will also have a booth (#12) set up at the conference, where attendees can engage with the team and explore the company’s extensive CDMO (Contract Development and Manufacturing Organization) and CRO (Contract Research Organization) services tailored specifically for the diagnostics industry. Attendees are encouraged to visit to discover ways in which DCN Dx can support their diagnostic endeavors, from product conception through to clinical support.

The Importance of Early Regulatory Engagement

One of the dual themes of DCN Dx's message at the tri-conference revolves around the importance of early regulatory engagement in the diagnostic development process. As outlined in Dr. Vaughan's presentations, the ability to navigate regulatory landscapes can significantly influence the progression of diagnostic products from conception to market introduction. The presentation aims to relate concrete examples highlighting the synergy between innovative assay development and the regulatory requirements that must be met for successful commercialization.

Invitation for Collaboration

Attendees looking for personalized discussions about their lateral flow CDMO and IVD CRO needs are invited to request a meeting during the event. This interaction aims to foster collaboration and offer targeted solutions that resonate with the unique requirements of each diagnostic development project.

About DCN Dx

Founded and based in Carlsbad, California, DCN Dx stands at the forefront of developing comprehensive solutions for the diagnostics sector. The company is recognized for its commitment to maintaining the highest standards of quality and customer satisfaction. They specialize in creating tailored assay systems and consumables designed specifically for point-of-use applications, demonstrating expertise particularly in lateral flow assays. Furthermore, DCN Dx’s clinical research team excels in planning and executing IVD clinical trials, covering every aspect from study design to data management, while adhering to stringent regulatory frameworks.

DCN Dx is redefining excellence in IVD services, supporting the diagnostics community with innovative solutions that meet the complex demands of the healthcare field. For more information on their services, please visit dcndx.com.

Conclusion

As the Precision Med Tri-Conference approaches, anticipation builds around what DCN Dx will showcase, and the knowledge that will be shared through their presentations. Industry professionals keen on understanding the latest in lateral flow diagnostics and regulatory strategies should not miss this opportunity to engage with DCN Dx.